Stonebridge Capital Advisors’s Quest Diagnostics DGX Stock Holding History

Stonebridge Capital Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-21	Closed	-$2.56K	–	370
2023 Q3	$2.56K	Hold	21	–	–	﹤0.01%	786
2023 Q2	$2.95K	Hold	21	–	–	﹤0.01%	771
2023 Q1	$2.97K	Hold	21	–	–	﹤0.01%	763
2022 Q4	$3.29K	Hold	21	–	–	﹤0.01%	748
2022 Q3	$3K	Hold	21	–	–	﹤0.01%	741
2022 Q2	$3K	Hold	21	–	–	﹤0.01%	769
2022 Q1	$3K	Hold	21	–	–	﹤0.01%	841
2021 Q4	$4K	Hold	21	–	–	﹤0.01%	766
2021 Q3	$3K	Hold	21	–	–	﹤0.01%	765
2021 Q2	$3K	Sell	21 -13	-38%	-$1.7K	﹤0.01%	746
2021 Q1	$4K	Buy	+34	New	+$4.19K	﹤0.01%	753
2020 Q3	–	Sell	-23	Closed	-$3K	–	313
2020 Q2	$3K	Hold	23	–	–	﹤0.01%	616
2020 Q1	$2K	Hold	23	–	–	﹤0.01%	633
2019 Q4	$2K	Hold	23	–	–	﹤0.01%	728
2019 Q3	$2K	Hold	23	–	–	﹤0.01%	714
2019 Q2	$2K	Buy	+23	New	+$2.21K	﹤0.01%	764

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Stonebridge Capital Advisors's DGX Position: Q4 2023 in Review

Stonebridge Capital Advisors sold out of Quest Diagnostics (DGX) in Q4 2023, closing a stake of 21 shares — an estimated $2.56K sold.

Stonebridge Capital Advisors first reported a position in DGX in Q2 2019 and held it in 16 quarters. The position peaked at $4K in Q4 2021. 827 funds tracked by Wall St. Rank hold DGX as of Q4 2023.

Stonebridge Capital Advisors reported no remaining Quest Diagnostics position as of Q4 2023 after selling out during the quarter.
Stonebridge Capital Advisors sold 21 Quest Diagnostics shares in Q4 2023, an estimated $2.56K.
Stonebridge Capital Advisors first reported a position in Quest Diagnostics in Q2 2019 and held it in 16 quarters.
Stonebridge Capital Advisors's Quest Diagnostics position peaked at $4K in Q4 2021.
827 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.